Dipeptidyl Peptidase-4 Inhibitors Associated with Lower Psoriatic Disease Risk in Type 2 Diabetes: A 13-Year Nationwide Cohort Study with Mechanistic Validation [PDF]
Acta Dermato-VenereologicaPsoriatic disease, encompassing psoriasis and -psoriatic arthritis, is a chronic inflammatory condition with bidirectional associations with type 2 diabetes mellitus.
Chih-Tsung Hung +5 more
doaj +2 more sources
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [PDF]
Diabetes & Metabolism Journal, 2022 Background It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment.
Sangmo Hong +3 more
doaj +1 more source
History of current non-insulin medications for diabetes mellitus [PDF]
Journal of Community Hospital Internal Medicine Perspectives, 2012 This article is a brief review of the current non-insulin agents for diabetes mellitus in the United States, namely, sulfonylureas, biguanides, thiazolidinediones, meglitinides, α-glucosidase inhibitors, glucacon-like peptide-1 receptor agonists ...
Celeste C. L. Quianzon, Issam E. Cheikh
doaj +1 more source
Journal of Diabetes Investigation, 2020 Japan's guidelines emphasize tailored therapy, but do not guide physicians on the use of a specific regimen in drug‐naive patients. The role of long‐term initial therapy could be important in key elements of diabetes treatment, such as continuation of ...
Takeshi Horii +3 more
doaj +1 more source
Roles and Mechanisms of Dipeptidyl Peptidase 4 Inhibitors in Vascular Aging
Frontiers in Endocrinology, 2021 Vascular aging is characterized by alterations in the constitutive properties and biological functions of the blood vessel wall. Endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) are indispensability elements in the inner layer and the ...
Fen Cao +3 more
doaj +1 more source
Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
Indian Journal of Endocrinology and Metabolism, 2014 The pharmacological actions of the glucagon-like peptide-1 receptor agonists (GLP-1RA) are largely predictable as they interact directly with GLP-1 receptors on beta cells to mediate their glucose lowering effects by increasing GLP-1 in pharmacological ...
Awadhesh Kumar Singh
doaj +1 more source
Journal of Diabetes Investigation, 2020 Aims/Introduction To explore the factors associated with the glucose‐lowering efficacy of sitagliptin treatment in Japanese patients with type 2 diabetes mellitus.
Naoko Tajima +5 more
doaj +1 more source
Systematic review of clinical and economic effectiveness of vildagliptin in type 2 diabetic patients with poor glycemic control on monotherapy with metformin [PDF]
Ķazaķstannyṇ Klinikalyķ Medicinasy, 2018 Aim: A study was conducted to assess the clinical and economic effectiveness of vildagliptin in adults with type 2 diabetes mellitus (T2DM) with poor glycemic control against the metformin monotherapy.
Alima Almadiyeva +3 more
doaj +1 more source
The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease
Frontiers in Immunology, 2015 Despite major advances in the understanding of the molecular mechanisms that underpin the development of diabetic kidney disease, current best practice still leaves a significant proportion of patients with end stage kidney disease requiring renal ...
Usha ePanchapakesan, Carol ePollock
doaj +1 more source
Journal of Diabetes Investigation, 2022 Aims/Introduction The union of dipeptidyl peptidase‐4 inhibitors and insulin in patients with type 2 diabetes and chronic kidney disease provides satisfactory glucose management without increasing adverse events (AEs).
Xianling Zhou +4 more
doaj +1 more source